These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8920810)

  • 21. [New directions in the study of immunity in dysentery].
    Pokrovskiĭ VI; Godovannyĭ BA; Iushchuk ND
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Apr; (4):6-12. PubMed ID: 6346759
    [No Abstract]   [Full Text] [Related]  

  • 22. [The determination in saliva of IgA antibodies to Shigella ribosomes for the diagnosis of dysentery].
    Salamatova SA; Sukhoroslova LI; Chernokhvostova EV; Levenson VI
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jun; (6):59-62. PubMed ID: 1887713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IpaD-loaded N-trimethyl Chitosan Nanoparticles Can Efficiently Protect Guinea Pigs against Shigella flexneri.
    Akbari MR; Saadati M; Honari H; Ghorbani HM
    Iran J Immunol; 2019 Sep; 16(3):212-224. PubMed ID: 31552830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live non-invasive Shigella dysenteriae 1 strain induces homologous protective immunity in a guinea pig colitis model.
    Barman S; Kumar R; Chowdhury G; Rani Saha D; Wajima T; Hamabata T; Ramamurthy T; Balakrish Nair G; Takeda Y; Koley H
    Microbiol Immunol; 2011 Oct; 55(10):683-93. PubMed ID: 21806676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella.
    Felegary A; Nazarian S; Kordbacheh E; Fathi J; Minae ME
    Int Immunopharmacol; 2021 Nov; 100():108132. PubMed ID: 34508943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.
    Ledov VA; Golovina ME; Markina AA; Knirel YA; L'vov VL; Kovalchuk AL; Aparin PG
    Vaccine; 2019 Feb; 37(8):1062-1072. PubMed ID: 30670300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shigellosis in Vietnam: seroepidemiologic studies with use of lipopolysaccharide antigens in enzyme immunoassays.
    Lindberg AA; Cam PD; Chan N; Phu LK; Trach DD; Lindberg G; Karlsson K; Kärnell A; Ekwall E
    Rev Infect Dis; 1991; 13 Suppl 4():S231-7. PubMed ID: 2047643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serologic response of patients with shiga dysentery.
    Cáceres A; Mata LJ
    J Infect Dis; 1974 Apr; 129(4):439-43. PubMed ID: 4593873
    [No Abstract]   [Full Text] [Related]  

  • 29. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.
    Pozsgay V; Chu C; Pannell L; Wolfe J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 1999 Apr; 96(9):5194-7. PubMed ID: 10220442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.
    Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB
    Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

  • 33. Serum enterotoxin-neutralizing antibody in human shigellosis.
    Keusch GT; Jacewicz M
    Nat New Biol; 1973 Jan; 241(105):31-2. PubMed ID: 4572837
    [No Abstract]   [Full Text] [Related]  

  • 34. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides.
    Oberhelman RA; Kopecko DJ; Salazar-Lindo E; Gotuzzo E; Buysse JM; Venkatesan MM; Yi A; Fernandez-Prada C; Guzman M; León-Barúa R
    Infect Immun; 1991 Jul; 59(7):2341-50. PubMed ID: 2050402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.
    Wahid R; Simon JK; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Clin Immunol; 2013 Jul; 148(1):35-43. PubMed ID: 23649043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody response to outer membrane proteins in Shigella dysenteriae type 1 infection with special reference to appearance of murine antibodies.
    Chakrabarti S; Sinha AK
    Indian J Med Res; 1996 Jul; 104():142-7. PubMed ID: 8783518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
    J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies specific for Shigella flexneri lipopolysaccharides: clones binding to type IV, V, and VI antigens, group 3,4 antigen, and an epitope common to all Shigella flexneri and Shigella dysenteriae type 1 stains.
    Carlin NI; Lindberg AA
    Infect Immun; 1987 Jun; 55(6):1412-20. PubMed ID: 2437036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivated and subunit vaccines to prevent shigellosis.
    Kaminski RW; Oaks EV
    Expert Rev Vaccines; 2009 Dec; 8(12):1693-704. PubMed ID: 19943764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.